Table 4.
Clinical outcome of seven glioblastomas patients with MET amplification
| Sex/Age | Operation | Initial Dx | Final Dx | Recur | PFS (months) | OS (months) | Outcome |
|---|---|---|---|---|---|---|---|
| F/40 | GTR | GBM, conventional | GBM-IDHw | No | 5.1 | 5.1 | DOD |
| M/65 | Biopsy | GBM, conventional | GBM-IDHw | No | 3.9 | 3.9 | DOD |
| M/49 | GTR | GBM, conventional | GBM-IDHw | Yes | 81.2 | 82.4 | DOD |
| M/77 | Biopsy | GBM, conventional | GBM-IDHw | No | 15.4 | 15.4 | DOD |
| F/21 | PR | GBM, epithelioid | GBM-IDHw | Yes | 7.7 | 43.8 | Alive |
| F/41 | PR | LO | AA→GBM-IDHm | Yes | 89.6 (from oligo to GBM) | 124 (from LO to DOD) | DOD |
| 29 (from GBM to DOD) | DOD | ||||||
| F/47 | PR | DA | DA→GBM-IDHm | Yes | 19.8 (from DA to AA) | 65.2 (from DA to DOD) | DOD |
| 40 (from AA to GBM) | 7 (from GBM to DOD) |
GBM: glioblastoma, IDHw: isocitrate dehydrogenase wild type, IDHm: IDH mutant, GTR: gross total removal, PR: partial removal, PFS: progression free survival, OS: overall survival, DOD: dead of disease, LO: low grade (grade II) oligodendroglioma, DA: diffuse astrocytoma, AA: anaplastic astrocytoma.